Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology
Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. They have classically been prepared using a thin-film hydration method with an average particle size of 100–200...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/11/2291 |
| _version_ | 1797466830767390720 |
|---|---|
| author | Yimei Jia Gerard Agbayani Vandana Chandan Umar Iqbal Renu Dudani Hui Qian Zygmunt Jakubek Kenneth Chan Blair Harrison Lise Deschatelets Bassel Akache Michael J. McCluskie |
| author_facet | Yimei Jia Gerard Agbayani Vandana Chandan Umar Iqbal Renu Dudani Hui Qian Zygmunt Jakubek Kenneth Chan Blair Harrison Lise Deschatelets Bassel Akache Michael J. McCluskie |
| author_sort | Yimei Jia |
| collection | DOAJ |
| description | Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. They have classically been prepared using a thin-film hydration method with an average particle size of 100–200 nm. In this study, we developed methods to generate SLA archaeosomes at different sizes, i.e., 30 nm and 100 nm, via microfluidic mixing technology and evaluated their physicochemical characteristics, as well as adjuvant activity and in vivo biodistribution in mice. Archaeosomes, prepared using thin-film and microfluidic mixing techniques, had similar nanostructures and physicochemical characteristics, with both appearing stable during the course of this study when stored at 4 °C or 37 °C. They also demonstrated similar adjuvant activity when admixed with ovalbumin antigen and used to immunize mice, generating equivalent antigen-specific immune responses. Archaeosomes, labeled with CellVue<sup>TM</sup> NIR815, had an equivalent biodistribution with both sizes, namely the highest signal at the injection site at 24 h post injection, followed by liver, spleen and inguinal lymph node. The presence of SLA archaeosomes of either size helped to retain OVA antigen (OVA-Cy5.5) longer at the injection site than unadjuvanted OVA. Overall, archaeosomes of two sizes (30 nm and 100 nm) prepared using microfluidic mixing maintained similar physicochemical properties, adjuvant activity and biodistribution of antigen, in comparison to those compared by the conventional thin film hydration method. This suggests that microfluidics based approaches could be applied to generate consistently sized archaeosomes for use as a vaccine adjuvant. |
| first_indexed | 2024-03-09T18:45:15Z |
| format | Article |
| id | doaj.art-9b2869dec3804fa1933b073d3c4f271c |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T18:45:15Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-9b2869dec3804fa1933b073d3c4f271c2023-11-24T06:19:46ZengMDPI AGPharmaceutics1999-49232022-10-011411229110.3390/pharmaceutics14112291Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic TechnologyYimei Jia0Gerard Agbayani1Vandana Chandan2Umar Iqbal3Renu Dudani4Hui Qian5Zygmunt Jakubek6Kenneth Chan7Blair Harrison8Lise Deschatelets9Bassel Akache10Michael J. McCluskie11Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaNanotechnology Research Centre, National Research Council Canada, Edmonton, AB T6G2M9, CanadaMetrology Research Centre, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A0R6, CanadaArchaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. They have classically been prepared using a thin-film hydration method with an average particle size of 100–200 nm. In this study, we developed methods to generate SLA archaeosomes at different sizes, i.e., 30 nm and 100 nm, via microfluidic mixing technology and evaluated their physicochemical characteristics, as well as adjuvant activity and in vivo biodistribution in mice. Archaeosomes, prepared using thin-film and microfluidic mixing techniques, had similar nanostructures and physicochemical characteristics, with both appearing stable during the course of this study when stored at 4 °C or 37 °C. They also demonstrated similar adjuvant activity when admixed with ovalbumin antigen and used to immunize mice, generating equivalent antigen-specific immune responses. Archaeosomes, labeled with CellVue<sup>TM</sup> NIR815, had an equivalent biodistribution with both sizes, namely the highest signal at the injection site at 24 h post injection, followed by liver, spleen and inguinal lymph node. The presence of SLA archaeosomes of either size helped to retain OVA antigen (OVA-Cy5.5) longer at the injection site than unadjuvanted OVA. Overall, archaeosomes of two sizes (30 nm and 100 nm) prepared using microfluidic mixing maintained similar physicochemical properties, adjuvant activity and biodistribution of antigen, in comparison to those compared by the conventional thin film hydration method. This suggests that microfluidics based approaches could be applied to generate consistently sized archaeosomes for use as a vaccine adjuvant.https://www.mdpi.com/1999-4923/14/11/2291archaeosomevaccine adjuvantsulfated lactosyl archaeolbio-distributionglycolipidliposome |
| spellingShingle | Yimei Jia Gerard Agbayani Vandana Chandan Umar Iqbal Renu Dudani Hui Qian Zygmunt Jakubek Kenneth Chan Blair Harrison Lise Deschatelets Bassel Akache Michael J. McCluskie Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology Pharmaceutics archaeosome vaccine adjuvant sulfated lactosyl archaeol bio-distribution glycolipid liposome |
| title | Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology |
| title_full | Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology |
| title_fullStr | Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology |
| title_full_unstemmed | Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology |
| title_short | Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology |
| title_sort | evaluation of adjuvant activity and bio distribution of archaeosomes prepared using microfluidic technology |
| topic | archaeosome vaccine adjuvant sulfated lactosyl archaeol bio-distribution glycolipid liposome |
| url | https://www.mdpi.com/1999-4923/14/11/2291 |
| work_keys_str_mv | AT yimeijia evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT gerardagbayani evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT vandanachandan evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT umariqbal evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT renududani evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT huiqian evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT zygmuntjakubek evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT kennethchan evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT blairharrison evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT lisedeschatelets evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT basselakache evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology AT michaeljmccluskie evaluationofadjuvantactivityandbiodistributionofarchaeosomespreparedusingmicrofluidictechnology |